BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 7536492)

  • 1. Predictive value for treatment outcome in acute myeloid leukemia of cellular daunorubicin accumulation and P-glycoprotein expression simultaneously determined by flow cytometry.
    Guerci A; Merlin JL; Missoum N; Feldmann L; Marchal S; Witz F; Rose C; Guerci O
    Blood; 1995 Apr; 85(8):2147-53. PubMed ID: 7536492
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anthracycline drugs and MDR expression in human leukemia.
    Pogliani EM; Belotti D; Rivolta GF; Maffè PF; Corneo G
    Cytotechnology; 1996; 19(3):229-35. PubMed ID: 8862011
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Overexpression of the major vault transporter protein lung-resistance protein predicts treatment outcome in acute myeloid leukemia.
    List AF; Spier CS; Grogan TM; Johnson C; Roe DJ; Greer JP; Wolff SN; Broxterman HJ; Scheffer GL; Scheper RJ; Dalton WS
    Blood; 1996 Mar; 87(6):2464-9. PubMed ID: 8630412
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of the expression of P glycoprotein, the multidrug resistance-related protein, bcl-2, mutant p53, and heat shock protein 27 on response to induction therapy and long-term survival in patients with de novo acute myeloid leukemia.
    Kasimir-Bauer S; Beelen D; Flasshove M; Noppeney R; Seeber S; Scheulen ME
    Exp Hematol; 2002 Nov; 30(11):1302-8. PubMed ID: 12423683
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of the clinical relevance of the expression and function of P-glycoprotein, multidrug resistance protein and lung resistance protein in patients with primary acute myelogenous leukemia.
    Tsimberidou AM; Paterakis G; Androutsos G; Anagnostopoulos N; Galanopoulos A; Kalmantis T; Meletis J; Rombos Y; Sagriotis A; Symeonidis A; Tiniakou M; Zoumbos N; Yataganas X
    Leuk Res; 2002 Feb; 26(2):143-54. PubMed ID: 11755464
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multidrug resistant cells with high proliferative capacity determine response to therapy in acute myeloid leukemia.
    te Boekhorst PA; Löwenberg B; van Kapel J; Nooter K; Sonneveld P
    Leukemia; 1995 Jun; 9(6):1025-31. PubMed ID: 7541095
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunophenotypic evidence of leukemia after induction therapy predicts relapse: results from a prospective Children's Cancer Group study of 252 patients with acute myeloid leukemia.
    Sievers EL; Lange BJ; Alonzo TA; Gerbing RB; Bernstein ID; Smith FO; Arceci RJ; Woods WG; Loken MR
    Blood; 2003 May; 101(9):3398-406. PubMed ID: 12506020
    [TBL] [Abstract][Full Text] [Related]  

  • 8. P-glycoprotein expression and prognostic value in acute myeloid leukemia.
    Senent L; Jarque I; Martín G; Sempere A; González-García Y; Gomis F; Pérez-Sirvent M; De La Rubia J; Sanz MA
    Haematologica; 1998 Sep; 83(9):783-7. PubMed ID: 9825574
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A new PCR MIMIC strategy to quantify low mdr1 mRNA levels in drug resistant cell lines and AML blast samples.
    Illmer T; Schaich M; Oelschlägel U; Nowak R; Renner U; Ziegs B; Subat S; Neubauer A; Ehninger G
    Leuk Res; 1999 Jul; 23(7):653-63. PubMed ID: 10400187
    [TBL] [Abstract][Full Text] [Related]  

  • 10. P-glycoprotein and multidrug resistance-associated protein, but not lung resistance protein, lower the intracellular daunorubicin accumulation in acute myeloid leukaemic cells.
    Borg AG; Burgess R; Green LM; Scheper RJ; Liu Yin JA
    Br J Haematol; 2000 Jan; 108(1):48-54. PubMed ID: 10651723
    [TBL] [Abstract][Full Text] [Related]  

  • 11. FAB M4 and high CD14 surface expression is associated with high cellular resistance to Ara-C and daunorubicin: implications for clinical outcome in acute myeloid leukaemia.
    Nørgaard JM; Olesen LH; Olesen G; Meyer K; Kristensen JS; Bendix K; Pedersen B; Kjeldsen E; Hokland P
    Eur J Haematol; 2001 Oct; 67(4):221-9. PubMed ID: 11860442
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Study of apoptosis-related responses of leukemic blast cells to in vitro anthracycline treatment.
    Belaud-Rotureau MA; Durrieu F; Labroille G; Lacombe F; Fitoussi O; Agape P; Marit G; Reiffers J; Belloc F
    Leukemia; 2000 Jul; 14(7):1266-75. PubMed ID: 10914552
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low frequency of activity of P-glycoprotein (P-170) in acute lymphoblastic leukemia compared to acute myeloid leukemia.
    Ludescher C; Eisterer W; Hilbe W; Gotwald M; Hofmann J; Zabernigg A; Cianfriglia M; Thaler J
    Leukemia; 1995 Feb; 9(2):350-6. PubMed ID: 7869774
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Correlation between CD34 expression and chromosomal abnormalities but not clinical outcome in acute myeloid leukemia.
    Fruchart C; Lenormand B; Bastard C; Boulet D; Lesesve JF; Callat MP; Stamatoullas A; Monconduit M; Tilly H
    Am J Hematol; 1996 Nov; 53(3):175-80. PubMed ID: 8895688
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Predictive value of intracellular accumulation of daunorubicin and P-glycoprotein expression simultaneously determined by flow cytometry in adult acute myeloid leukemias].
    Guerci A; Merlin JL; Missoum N; Feldmann L; Marchal S; Guerci O
    Ann Biol Clin (Paris); 1996; 54(1):17-9. PubMed ID: 8731790
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression and functional activity of P-glycoprotein in adult acute myelogenous leukemia patients.
    Nuessler V; Gullis E; Pelka-Fleischer R; del Valle F; Diem H; Beyerlein S; Zwierzina H; Wilmanns W
    Ann Hematol; 1997; 75(1-2):17-26. PubMed ID: 9322679
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Functional multidrug resistance phenotype associated with combined overexpression of Pgp/MDR1 and MRP together with 1-beta-D-arabinofuranosylcytosine sensitivity may predict clinical response in acute myeloid leukemia.
    Schuurhuis GJ; Broxterman HJ; Ossenkoppele GJ; Baak JP; Eekman CA; Kuiper CM; Feller N; van Heijningen TH; Klumper E; Pieters R
    Clin Cancer Res; 1995 Jan; 1(1):81-93. PubMed ID: 9815890
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predominance of functional multidrug resistance (MDR-1) phenotype in CD34+ acute myeloid leukemia cells.
    te Boekhorst PA; de Leeuw K; Schoester M; Wittebol S; Nooter K; Hagemeijer A; Löwenberg B; Sonneveld P
    Blood; 1993 Nov; 82(10):3157-62. PubMed ID: 7693039
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro drug resistance in acute myeloid and chronic B-lymphocytic leukaemic blasts and in normal blood and marrow populations.
    Baines P; Limaye M; Hoy T; Padua RA; Whittaker J; al-Sabah A; Burnett A
    Leuk Res; 1994 Sep; 18(9):683-91. PubMed ID: 7934144
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The prognostic value of cytogenetics is reinforced by the kind of induction/consolidation therapy in influencing the outcome of acute myeloid leukemia--analysis of 848 patients.
    Visani G; Bernasconi P; Boni M; Castoldi GL; Ciolli S; Clavio M; Cox MC; Cuneo A; Del Poeta G; Dini D; Falzetti D; Fanin R; Gobbi M; Isidori A; Leoni F; Liso V; Malagola M; Martinelli G; Mecucci C; Piccaluga PP; Petti MC; Rondelli R; Russo D; Sessarego M; Specchia G; Testoni N; Torelli G; Mandelli F; Tura S
    Leukemia; 2001 Jun; 15(6):903-9. PubMed ID: 11417475
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.